GlassScriptPhysician profile
Natalie Chastant
NPI 1669702403
$5,546.59
in general payments reported to CMS, 2019-2025
50 companies · $2,615 in 2025
The $2,615 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,207 · 2024: $1,725 · 2025: $2,615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,912 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,911.80 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $438.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,396.01 | 2023-2025 | |
| Janssen Biotech, INC. | $471.88 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Lilly USA, LLC | $373.96 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $373.28 | 2023-2025 | Jakafi, Monjuvi |
| Daiichi Sankyo INC. | $230.82 | 2024-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $224.46 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Stemline Therapeutics INC. | $169.64 | 2023-2025 | Elzonris, Orserdu |
| Glaxosmithkline, LLC. | $162.44 | 2023-2025 | Jemperli, Ojjaara |
| Abbvie INC. | $152.82 | 2023-2025 | |
| Beigene USA, INC. | $145.43 | 2023-2024 | Brukinsa, Tevimbra |
| Pfizer INC. | $135.53 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.52 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Myriad Genetic Laboratories, INC. | $113.83 | 2023-2024 | Myrisk |
| Genmab U.S., INC. | $109.84 | 2024 | Epkinly |
| Gilead Sciences, INC. | $104.64 | 2023-2025 | Trodelvy |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $94.42 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $80.09 | 2024-2025 | Libtayo |
| Pharmaessentia USA Corporation | $67.33 | 2024-2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $66.08 | 2024-2025 | Monoferric |
| Janssen Scientific Affairs, LLC | $64.57 | 2023 | Darzalex |
| Astrazeneca Pharmaceuticals LP | $57.52 | 2023-2025 | Calquence, Lynparza |
| Celgene Corporation | $54.04 | 2023-2024 | Reblozyl, Pomalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.90 | 2023-2025 | Gilotrif |
| Karyopharm Therapeutics INC. | $48.06 | 2023-2024 | Xpovio |
| Geron Corporation | $46.98 | 2025 | Rytelo |
| E.R. Squibb & Sons, L.L.C. | $44.24 | 2024-2025 | Opdivo |
| Eisai INC. | $42.36 | 2023 | |
| Array Biopharma INC | $41.92 | 2023-2025 | Mektovi, Lorbrena, Xalkori |
| Genzyme Corporation | $41.37 | 2023-2024 | |
| Seagen INC. | $38.70 | 2023 | Padcev, Adcetris |
| Puma Biotechnology, INC. | $34.58 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $29.87 | 2024 | Ultomiris |
| Mirati Therapeutics, INC. | $28.52 | 2024 | Krazati |
| Amgen INC. | $27.79 | 2023 | Vectibix, Nplate |
| Exelixis INC. | $24.02 | 2025 | Cabometyx |
| Morphosys, US INC. | $22.52 | 2023 | Monjuvi |
| Servier Pharmaceuticals LLC | $22.51 | 2024 | |
| Sobi, INC | $22.18 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.25 | 2024 | Pyrukynd |
| Beone Medicines USA, INC. | $21.23 | 2025 | Tevimbra |
| Jazz Pharmaceuticals INC. | $20.38 | 2023 | |
| Secura Bio, INC. | $19.76 | 2024 | Copiktra |
| Taiho Oncology, INC. | $19.22 | 2025 | |
| Adaptive Biotechnologies Corporation | $18.53 | 2023 | Clonoseq |
| Kyowa Kirin, INC. | $18.18 | 2023 | Poteligeo |
| Recordati_rare_diseases_inc. | $16.97 | 2025 | Sylvant |
| Rigel Pharmaceuticals, INC. | $15.66 | 2024 | Rezlidhia, Tavalisse |
| Immunocore Limited | $15.37 | 2025 | Kimmtrak |
| Aveo Pharmaceuticals, INC. | $13.26 | 2024 | |
| Pharmaand Gmbh | $10.11 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Chastant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.